Skip to main content

Advertisement

Table 1 Details of transcatheter thrombolysis therapy

From: Transcatheter thrombolysis combined with damage control surgery for treatment of acute mesenteric venous thrombosis associated with bowel necrosis: a retrospective study

No. of patients location of thrombosis Route of thrombolysis Days of SMA thrombolysis Agent and dose of SMA thrombolysis Days of SMV thrombolysis Agent and dose of SMV thrombolysis Total dose of thrombolytics Days of thrombolytic infusion
1 PV + SPV + SMV SMA (first) + PT (next) 6 Urokinase (3,200,000 IU) 5 Urokinase (2,800,000 IU) Urokinase (6,000,000 IU) 11
2 PV + SMV + IVC SMA + PT 3 Urokinase (600,000 IU) 7 Urokinase (2,600,000 IU) Urokinase (3,200,000 IU) 7
3 SMV PT + SMA 6 urokinase (1,700,000 IU) 6 Urokinase (1,200,000 IU) Urokinase (2,900,000 IU) 6
4 PV + SPV + SMV + IVC SMA 5 Alteplase (60 mg) + urokinase (1,200,000 IU) - - Alteplase (60 mg) + urokinase (1,200,000 IU) 5
5 PV + SMV + IVC TI + SMA 3 Alteplase (10 mg) + urokinase (600,000 IU) 6 Alteplase (110 mg) + urokinase (400,000 IU) Alteplase (120 mg) + urokinase (1,000,000 IU) 6
6 PV + SPV + SMV PT + SMA 5 Alteplase (30 mg) 5 Alteplase (50 mg) Alteplase (80 mg) 5
  1. SMV superior mesenteric vein, PV portal vein, SPV splenic vein, IVC inferior vena cave, PT percutaneous transhepatic route, TI transjugular intrahepatic route, SMA superior mesenteric arterial route